TY - JOUR
T1 - The evolution of the European Respiratory Journal
T2 - weathering the publishing pandemic
AU - Kolb, Martin
AU - Chalmers, James D.
AU - Humbert, Marc
N1 - Funding Information:
Conflict of interest: M. Kolb has received grants and personal fees from Roche, Boehringer Ingelheim, GSK, Gilead, Prometic (now Liminal Biosciences) and Pieris; grants from Avalyn; and personal fees from AstraZeneca, Novartis, Cipla, Bluefin Biomedicine, Algernon and Medscape. J.D. Chalmers has received research grants from GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Pfizer, Grifols, Bayer AG, Polyphor and Insmed; and received consultancy, congress travel or speaker fees from GlaxoSmithKline, Bayer Healthcare, Aradigm Corporation, Grifols, Pfizer, Boehringer Ingelheim, Napp and Insmed. M. Humbert reports grants and personal fees from Bayer/Merck and GSK, personal fees from Actelion Pharmaceuticals Ltd/Johnson & Johnson, Arena Pharmaceuticals Ltd, Pfizer, United Therapeutics, Astrazeneca, Novartis, Roche/Genentech, Sanofi/Regeneron and Teva; in addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - The year 2020 has imposed challenges on society and healthcare systems as never encountered for many decades: the word “COVID” will stick in our memories long after it (hopefully) has been controlled. The pandemic has been a tragedy in terms of lives lost, economic damage and the long term consequences to health that are only now being realised. We mourn with our readers the lost colleagues, family members, friends and loved ones. What is the role of a scientific journal in a situation such as this? From early in the pandemic the ERJ has played a key role in the mission of the European Respiratory Society to provide timely information and guidelines to clinicians and an outlet for important scientific research. We hope that the work published in the ERJ in the past year has helped to inform, educate and entertain our readers during the most challenging period of all of our professional lives.
AB - The year 2020 has imposed challenges on society and healthcare systems as never encountered for many decades: the word “COVID” will stick in our memories long after it (hopefully) has been controlled. The pandemic has been a tragedy in terms of lives lost, economic damage and the long term consequences to health that are only now being realised. We mourn with our readers the lost colleagues, family members, friends and loved ones. What is the role of a scientific journal in a situation such as this? From early in the pandemic the ERJ has played a key role in the mission of the European Respiratory Society to provide timely information and guidelines to clinicians and an outlet for important scientific research. We hope that the work published in the ERJ in the past year has helped to inform, educate and entertain our readers during the most challenging period of all of our professional lives.
UR - http://www.scopus.com/inward/record.url?scp=85100658340&partnerID=8YFLogxK
U2 - 10.1183/13993003.00084-2021
DO - 10.1183/13993003.00084-2021
M3 - Editorial
C2 - 33509907
VL - 57
JO - European Respiratory Journal
JF - European Respiratory Journal
SN - 0903-1936
IS - 1
M1 - 2100084
ER -